XML 36 R12.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Share capital | 12 Months Ended
--- | ---
Nov. 30, 2023
Share-Based Payment Arrangement [Abstract] |
Share capital | 6) Share capital Authorized: unlimited common shares, no par value ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | in thousands of dollars, except share amounts | ​
​ | ​ | Number of shares | ​ | ​ | Ascribed value | ​
​ |  | ​ |  |  | $ |
November 30, 2022 |  | 146,225,035 | ​ | ​ | 182,178 | ​
Private Placement, net of share issue cost | ​ | 5,854,545 | ​ | ​ | 3,115 | ​
Restricted Share Units | ​ | 3,091,614 | ​ | ​ | 1,911 | ​
Deferred Share Units | ​ | 415,056 | ​ | ​ | 468 | ​
NovaGold deferred share units conversion | ​ | 1,130 | ​ | ​ | 4 | ​
Services settled by common shares | ​ | 195,105 | ​ | ​ | 99 | ​
Joint venture equity contribution (note 4(b)) | ​ | 143,505 | ​ | ​ | 111 | ​
November 30, 2023, issued and outstanding | ​ | 155,925,990 | ​ | ​ | 187,886 | ​
​ On April 30, 2012, under the NovaGold Arrangement, Trilogy committed to issue common shares to satisfy holders of NovaGold deferred share units (“NovaGold DSUs”), once vested, on record as of the close of business April 27, 2012. When vested, Trilogy committed to deliver one common share to the holder for every six shares of NovaGold the holder is entitled to receive, rounded down to the nearest whole number. As of November 30, 2023, a total of 5,144 NovaGold DSUs remain outstanding representing a right to receive 859 Common Shares in Trilogy, which will settle upon certain directors retiring from NovaGold’s board. (a)Common shares issuance On April 25, 2023, the Company completed a non-brokered private placement of 5,854,545 Common Shares at a price of $0.55 per Common Share for gross proceeds of $3.2 million and net proceeds of $3.1 million. Financing costs consisted of legal and stock exchange fees. (b)Stock options The Company has a stock option plan providing for the issuance of options with a rolling maximum number equal to 10% of the issued and outstanding Common Shares at any given time. The Company may grant options to its directors, officers, employees and service providers. The exercise price of each option cannot be lower than the greater of market price or fair market value of the Common Shares (as such terms are defined in the plan) at the date of the option grant. The number of Common Shares optioned to any single optionee may not exceed 10% of the issued and outstanding Common Shares at the date of grant. The options are exercisable for a maximum of five years from the date of grant and may be subject to vesting provisions. During the year ended November 30, 2023, the Company granted 3,230,000 stock options (2022 – 1,734,500 stock options, 2021 – 3,374,150) at an exercise price of CDN$0.78 (2022 - CDN$2.21, 2021 – CDN$2.52) to employees, consultants and directors exercisable for a period of five years with various vesting terms from immediate vesting to over a two-year period. The fair value attributable to options granted in 2023 was $0.27 (2022 -$0.71, 2021 - $0.84). The fair value of the stock options recognized has been estimated using the Black-Scholes option pricing model. Assumptions used in the pricing model for the year are as provided below. ​
​ | ​ | ​
​ |  | November 30, 2023
Risk-free interest rates |  | 3.49%
Exercise price |  | CDN$0.78
Expected life |  | 3 years
Expected volatility |  | 67.7%
Expected dividends |  | Nil
​ The Company recognized a stock option expense of $0.9 million for the year ended November 30, 2023 (2022 - $1.4 million; 2021 - $3.3 million), net of forfeitures. As of November 30, 2023, there were 2,131,757 unvested options outstanding with a weighted average exercise price of CDN$1.02. The unvested stock option expense not yet recognized was $0.2 million. This expense is expected to be recognized over the next twelve months. A summary of the Company’s stock option plan and changes during the year ended is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | November 30, 2023 | ​
​ | ​ | ​ | ​ | ​ | Weighted average | ​
​ | ​ | ​ | ​ | ​ | exercise price | ​
​ |  | Number of options |  |  | CDN$ |
Balance – beginning of the year |  | 11,225,400 | ​ | ​ | 2.49 | ​
Granted |  | 3,230,000 | ​ | ​ | 0.78 | ​
Cancelled/forfeited |  | (636,000) | ​ | ​ | 2.55 | ​
Expired |  | (1,170,000) | ​ | ​ | 1.43 | ​
Balance – end of the year |  | 12,649,400 | ​ | ​ | 2.15 | ​
​ There were no stock options exercised during the year ended November 30, 2023. ​ The following table summarizes information about the stock options outstanding at November 30, 2023. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Outstanding | ​ | ​ | Exercisable | ​ | ​ | Unvested |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Weighted | ​ | ​ | ​ | ​ | ​ | Weighted | ​ | ​ | ​ |
​ | ​ | Number of | ​ | ​ | Weighted | ​ | ​ | average | ​ | ​ | Number of | ​ | ​ | average | ​ | ​ | Number of |
​ | ​ | outstanding | ​ | ​ | average years | ​ | ​ | exercise price | ​ | ​ | exercisable | ​ | ​ | exercise price | ​ | ​ | unvested | ​
Range of exercise price - CDN |  | options |  |  | to expiry |  |  | CDN$ |  |  | options |  |  | CDN$ |  |  | options |
$0.75 to $1.00 |  | 3,180,000 | ​ | ​ | 4.02 | ​ | ​ | 0.78 | ​ | ​ | 1,413,328 | ​ | ​ | 0.78 | ​ | ​ | 1,766,672 | ​
$2.01 to $2.50 |  | 2,220,250 | ​ | ​ | 2.28 | ​ | ​ | 2.27 | ​ | ​ | 1,855,165 | ​ | ​ | 2.27 | ​ | ​ | 365,085 | ​
$2.51 to $3.00 | ​ | 5,866,650 | ​ | ​ | 1.49 | ​ | ​ | 2.64 | ​ | ​ | 5,866,650 | ​ | ​ | 2.64 | ​ | ​ | — | ​
$3.01 to $3.41 | ​ | 1,382,500 | ​ | ​ | 1.06 | ​ | ​ | 3.03 | ​ | ​ | 1,382,500 | ​ | ​ | 3.03 | ​ | ​ | — | ​
​ | ​ | 12,649,400 | ​ | ​ | 2.22 | ​ | ​ | 2.15 | ​ | ​ | 10,517,643 | ​ | ​ | 2.38 | ​ | ​ | 2,131,757 | ​
​ The aggregate intrinsic value of vested share options (the market value less the exercise price) at November 30, 2023 was $nil (2022 - $nil, 2021 - $0.8 million) and the aggregate intrinsic value of exercised options for the year ended November 30, 2023 was $nil (2022 - $0.04 million, 2021 - $1.4 million).
(c) | Restricted Share Units and Deferred Share Units
The Company has a Restricted Share Unit Plan (“RSU Plan”) and a Non-Executive Director Deferred Share Unit Plan (“DSU Plan”) to provide long-term incentives to employees, officers and directors. The RSU Plan and DSU Plan may be settled in cash and/or common shares at the Company’s election with each RSU and DSU entitling the holder to receive one common share of the Company or equivalent value. All units are accounted for as equity-settled awards. There were 4,640,089 RSUs granted during the fiscal year ended November 30, 2023 (2022 – 1,359,349, 2021 – nil). Directors were granted 1,283,023 DSUs throughout the year ended November 30, 2023 (2022 – 283,289, 2021 – 58,925) based on their election to receive 100% of their annual retainer in DSUs. A summary of the Company’s RSU and DSU Plan and changes during the year ended November 30, 2023 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Number of RSUs |  |  | Number of DSUs |
Balance – beginning of the year | ​ | 257,268 | ​ |  | 1,560,734 | ​
Granted |  | 4,640,089 | ​ | ​ | 1,283,023 | ​
Vested/Converted |  | (3,286,719) | ​ | ​ | (415,056) | ​
Balance – end of the year |  | 1,610,638 | ​ |  | 2,428,701 | ​
​ For the year ended November 30, 2023, Trilogy recognized a stock-based compensation expense of $3.0 million (2022 - $2.0 million, 2021 - $0.1 million).

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration